Skip to content

    Accretion Pharmaceuticals Q2 FY26 earnings call

    ACCPL
    Healthcare·18 Nov 2025
    Management Summary

    Accretion Pharmaceuticals delivered strong H1 FY26 results, with significant revenue and PAT growth driven by IPO-funded capacity expansion and strategic focus on CDMO and export markets. While EBITDA margins saw a temporary compression due to scaling costs, management is confident in recovery as the business matures. The company is aggressively pursuing product and plant registrations in new geographies to sustain future growth.

    Highlights

    5

    • H1 FY26 Net Revenue increased by 135.59% YoY to INR 43.74 crores, driven by strong volume expansion post IPO-funded capex and a richer product mix.

    • H1 FY26 Profit After Tax (PAT) grew 92.81% YoY to INR 4.75 crores, reflecting robust revenue traction.

    • The successful IPO in May 2025 raised INR 29.75 crores, which was deployed to enhance manufacturing capability, reduce debt, and strengthen working capital.

    • Achieved cGMP plant approval from Malawi, opening direct export opportunities and strengthening the company's CDMO position in the African market.

    • Production capacity increased by 40% post IPO, enabling better utilization and catering to expanded customer demand.

    Concerns

    2

    • H1 FY26 EBITDA margin compressed to 16.17% from FY25's 21%, attributed to product mix, volume focus, and scaling expenses.

    • Product and plant registration processes in new markets have long lead times, typically 1-2 years, which can delay market entry and revenue generation.

    Key financials

    Metrics

    10

    Periods

    2

    H1 FY26

    5
    • Net Revenue
      ₹43.74 Cr
      YoY+135.6%
    • EBITDA
      ₹7.07 Cr
      YoY+63%
    • EBITDA Margin
      16.2%
    • PAT
      ₹4.75 Cr
      YoY+92.8%
    • PAT Margin
      10.9%

    FY25

    5
    • Revenue
      ₹57.4 Cr
      YoY+70%
    • EBITDA Margin
      21%
    • PAT
      ₹6.8 Cr
    • PAT Margin
      12%
    • ROCE
      38%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Working capital days average around 190 days (180-190 for export, 140-150 for domestic). IPO proceeds strengthened working capital.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Revenue Growth Momentum
    Same momentum as H1 FY26 (135.59% YoY)
    		Medium
    Profitability
    EBITDA Margin
    20-22%
    		Medium
    Profitability
    PAT
    Closer to INR 10 crores
    		Low
    Capacity
    Production Capacity Increase
    40%
    		High
    Other
    Products under registration
    More than 100 products
    		High
    Geographical Expansion
    Plant Registration Pipeline
    Philippines, Ghana, Cameroon, Sierra Leone
    		High
    Market Share
    Branded Sales Contribution
    Increase for better margins
    		Medium

    What to watch in Q3 FY26

    5

    EBITDA Margin Recovery

    Next quarter/H2 FY26
    Current16.17% (H1 FY26)
    TargetTowards 20-22%

    Why it matters

    Indicates operational efficiency and ability to absorb scaling costs, crucial for sustained profitability.

    As of now we are having a 17% EBITDA margin. So, we are expecting by the time we will reach by that EBITDA margin.

    Risks & concerns

    2
    RiskSeverity

    EBITDA Margin Compression

    H1 FY26 EBITDA margin dropped to 16.17% from FY25's 21% due to product mix, volume focus, and scaling costs like product registration and development. — Management acknowledged

    medium

    Long Lead Times for Market Entry

    Plant and product registrations in new countries can take 1-2 years, potentially delaying revenue generation from these expansion efforts. — Management acknowledged

    medium

    Q&A highlights

    8

    “From the existing customers, we are more focusing on the more product mix, like we are increasing the product portfolio of the existing customers and that will eventually increase our sales revenue.”

    Clarifies the company's strategy for growth and market penetration as a new entrant.

    asked by Giri

    2 min read5 chapters

    Detailed Narrative

    01

    Strong H1 FY26 Performance Driven by IPO-led Expansion

    Accretion Pharmaceuticals reported a robust H1 FY26, with Net Revenue growing 135.59% YoY to INR 43.74 crores, and PAT increasing 92.81% YoY to INR 4.75 crores. This strong performance was attributed to the successful IPO in May 2025, which raised INR 29.75 crores. These funds were strategically deployed to upgrade manufacturing facilities, enhance capacity by 40%, and repay selected borrowings, reinforcing the company's financial foundation and operational capabilities.

    02

    Strategic Focus on CDMO and Export Markets

    The company operates as a CDMO, specializing in generic and branded formulations, serving over 30 countries. Management highlighted a strategic focus on direct exports and a diversified product portfolio across therapeutic areas like antibiotics, anti-inflammatory, and cardiac treatments. Recent cGMP plant approval from Malawi is expected to significantly contribute to export revenues and strengthen Accretion's position as a trusted CDMO partner in the African market.

    03

    Margin Dynamics and Future Outlook

    While H1 FY26 EBITDA margin stood at 16.17%, a decrease from FY25's 21%, management explained this was due to product mix, volume focus, and increased expenses related to product registration and development during the scaling-up phase. They aim to restore EBITDA margins to 20-22% as the business matures and these one-time📎 scaling costs normalize. The company expects to maintain the strong revenue growth momentum seen in H1 FY26 for the upcoming half year and beyond, with PAT projected to be closer to INR 10 crores for FY26.

    04

    Aggressive Product and Geographical Registration Pipeline

    Accretion Pharmaceuticals is actively pursuing market expansion through product and plant registrations. Over 100 products are currently under registration, and plant registrations are in the pipeline for high-potential markets like the Philippines, Ghana, Cameroon, and Sierra Leone. While these processes have a lead time of 1-2 years, management believes these efforts will drive future demand and growth, leveraging existing plant approvals in countries like Cambodia, Rwanda, Nigeria, and Malawi.

    05

    Working Capital Management and Branded Sales Ambition

    The company manages its working capital with an average of 190 days, with export operations typically requiring 180-190 days due to shipment and payment cycles, compared to 140-150 days for domestic sales. Accretion also expressed an ambition to increase its branded sales contribution, which currently forms a small portion of direct exports (~10%). Establishing its own brand name is seen as a key strategy to achieve better margins in the future.

    This is an AI-generated summary of a publicly available earnings call transcript.